세계의 히스톤 탈아세틸화효소(HDAC) 억제제 시장 보고서(2025년)

Histone deacetylase (HDAC) inhibitors are a category of compounds that inhibit the activity of histone deacetylase enzymes. These enzymes are responsible for the removal of acetyl groups from histone proteins, resulting in a more compact chromatin structure and decreased gene expression. By promoting hyperacetylation of histones, HDAC inhibitors generally lead to a more open chromatin structure, making DNA more accessible to transcription factors.

Histone deacetylase (HDAC) inhibitors are categorized into four main classes class I, class II, class III, and class IV HDACs. Class I HDACs primarily regulate gene expression by altering chromatin structure and are involved in numerous cellular processes. They are extensively researched for their potential use in treating cancer and other diseases. HDAC inhibitors can be administered orally or parenterally and are applied in fields such as oncology and neurology. They are utilized by various end users, including hospitals, academic and research institutes, and pharmaceutical companies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The histone deacetylase (HDAC) inhibitors market research report is one of a series of new reports from The Business Research Company that provides histone deacetylase (HDAC) inhibitors market statistics, including histone deacetylase (HDAC) inhibitors industry global market size, regional shares, competitors with a histone deacetylase (HDAC) inhibitors market share, detailed histone deacetylase (HDAC) inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the histone deacetylase (HDAC) inhibitors industry. This histone deacetylase (HDAC) inhibitors research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The histone deacetylase (hdac) inhibitors market size has grown strongly in recent years. It will grow from $1.23 billion in 2024 to $1.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to a rise in funding for epigenetic research, rising prevalence of drug-resistant cancers, rise in healthcare expenditure, increasing utilization of HDAC inhibitors in veterinary medicine, and increasing investment in bioinformatics.

The histone deacetylase (hdac) inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to the rising incidence of neurodegenerative disorders, growing awareness about cancer, rising investment in drug development, growing number of clinical trials, and increasing adoption of personalized medicine. Major trends in the forecast period include technological advancements, personalized medicine, cancer immunotherapy synergies, integration of digital health solutions, and bioinformatics.

The forecast of 7.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of cutting-edge lymphoma therapies by inflating prices of Histone Deacetylase (HDAC) Inhibitors(HDAC inhibitor) drugs developed in Switzerland and the UK, resulting in delayed oncology treatments and higher specialty pharmacy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of neurodegenerative disorders is expected to drive the growth of the histone deacetylase (HDAC) inhibitors market. Neurodegenerative disorders, which involve the progressive degeneration and death of neurons in the brain and spinal cord, result in cognitive and motor impairments. These include conditions like Alzheimer's disease, characterized by memory loss and cognitive decline due to amyloid plaques and tau tangles. The rise in neurodegenerative disorders is linked to factors such as aging, genetics, longevity, and environmental influences. HDAC inhibitors are being investigated as potential treatments for these disorders because of their ability to regulate gene expression and offer neuroprotective effects. For example, in August 2024, the Centers for Disease Control and Prevention (CDC), a US federal agency, reported that approximately 6.7 million older adults in the United States are currently living with Alzheimer's disease, a number projected to nearly double to 14 million by 2060. As a result, the growing incidence of neurodegenerative diseases is fueling the expansion of the HDAC inhibitors market.

Key players in the HDAC inhibitors market are concentrating on developing novel treatments, such as HDAC inhibitors for cancer therapy, to improve efficacy and minimize side effects. HDAC inhibitors are a class of drugs used in cancer therapy that work by blocking HDAC enzymes, which usually remove acetyl groups from histone proteins. This blockage results in increased acetylation of histones, altering chromatin structure and affecting gene expression. For example, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based firm specializing in pioneering cancer therapies, received new patents from the U.S. Patent and Trademark Office for HDAC inhibitors targeting cancer treatment. These new inhibitors are designed to target specific HDAC enzymes associated with cancer progression, aiming to disrupt abnormal gene expression linked to tumor development and spread. The patented compounds offer improved potency and selectivity, reducing off-target effects and enhancing safety for patients.

In June 2024, Italfarmaco SpA, a US-based pharmaceutical company, formed a partnership with Iktos SA for an undisclosed amount. This collaboration aims to accelerate drug discovery in non-oncological areas by utilizing AI to design advanced HDAC inhibitors. Iktos SA is a France-based technology company specializing in artificial intelligence solutions for medicinal chemistry and drug discovery.

Major companies operating in the histone deacetylase (HDAC) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.

North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (HDAC) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the histone deacetylase (HDAC) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The histone deacetylase (HDAC) inhibitors market consists of sales of valproic acid, hydroxamic acids, cyclic peptides, short-chain fatty acids, and benzamides. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Histone Deacetylase (HDAC) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on histone deacetylase (hdac) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for histone deacetylase (hdac) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The histone deacetylase (hdac) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Class: Class I HDACs; Class II HDACs; Class III HDACs; Class IV HDACs
• 2) By Route Of Administration: Oral HDAC Inhibitors; Parenteral HDAC Inhibitors
• 3) By Application: Oncology; Neurology; Other Applications
• 4) By End User: Hospitals; Academic And Research Institutes; Pharmaceutical Companies; Other End Users
• Subsegments:
• 1) By Class I HDACs: HDAC1; HDAC2; HDAC3; HDAC8
• 2) By Class II HDACs: HDAC4; HDAC5; HDAC6; HDAC7; HDAC9; HDAC10
• 3) By Class III HDACs (Sirtuins): SIRT1; SIRT2; SIRT3; SIRT4; SIRT5; SIRT6; SIRT7
• 4) By Class IV HDACs: HDAC11
• Companies Mentioned: Bristol-Myers Squibb Company; Novartis AG; Merck KGaA; Abcam plc; Pharmacyclics LLC; R&D Systems Inc.; Tenaya Therapeutics Inc.; Syndax Pharmaceuticals Inc.; Italfarmaco SpA; InvivoGen Corporation; TCI Chemicals (India) Pvt. Ltd.; 4SC AG; Medivir AB; Mirati Therapeutics Inc.; Spectrum Pharmaceuticals Inc.; Curis Inc.; Acetylon Pharmaceuticals Inc.; Oryzon Genomics SA; Xynomic Pharmaceuticals Inc.; Celleron Therapeutics Ltd.; Midatech Pharma PLC; Karus Therapeutics Ltd.; Shenzhen Chipscreen Biosciences Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Histone Deacetylase (HDAC) Inhibitors Market Characteristics

3. Histone Deacetylase (HDAC) Inhibitors Market Trends And Strategies

4. Histone Deacetylase (HDAC) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Histone Deacetylase (HDAC) Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Histone Deacetylase (HDAC) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Histone Deacetylase (HDAC) Inhibitors Market Growth Rate Analysis
• 5.4. Global Histone Deacetylase (HDAC) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Histone Deacetylase (HDAC) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Histone Deacetylase (HDAC) Inhibitors Total Addressable Market (TAM)

6. Histone Deacetylase (HDAC) Inhibitors Market Segmentation

• 6.1. Global Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Class I HDACs
• Class II HDACs
• Class III HDACs
• Class IV HDACs
• 6.2. Global Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral HDAC Inhibitors
• Parenteral HDAC Inhibitors
• 6.3. Global Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Neurology
• Others Applications
• 6.4. Global Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Academic And Research Institutes
• Pharmaceutical Companies
• Other End Users
• 6.5. Global Histone Deacetylase (HDAC) Inhibitors Market, Sub-Segmentation Of Class I HDACs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HDAC1
• HDAC2
• HDAC3
• HDAC8
• 6.6. Global Histone Deacetylase (HDAC) Inhibitors Market, Sub-Segmentation Of Class II HDACs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HDAC4
• HDAC5
• HDAC6
• HDAC7
• HDAC9
• HDAC10
• 6.7. Global Histone Deacetylase (HDAC) Inhibitors Market, Sub-Segmentation Of Class III HDACs (Sirtuins), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• SIRT1
• SIRT2
• SIRT3
• SIRT4
• SIRT5
• SIRT6
• SIRT7
• 6.8. Global Histone Deacetylase (HDAC) Inhibitors Market, Sub-Segmentation Of Class IV HDACs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HDAC11

7. Histone Deacetylase (HDAC) Inhibitors Market Regional And Country Analysis

• 7.1. Global Histone Deacetylase (HDAC) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Histone Deacetylase (HDAC) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Market

• 8.1. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Histone Deacetylase (HDAC) Inhibitors Market

• 9.1. China Histone Deacetylase (HDAC) Inhibitors Market Overview
• 9.2. China Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Histone Deacetylase (HDAC) Inhibitors Market

• 10.1. India Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Histone Deacetylase (HDAC) Inhibitors Market

• 11.1. Japan Histone Deacetylase (HDAC) Inhibitors Market Overview
• 11.2. Japan Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Histone Deacetylase (HDAC) Inhibitors Market

• 12.1. Australia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Histone Deacetylase (HDAC) Inhibitors Market

• 13.1. Indonesia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Histone Deacetylase (HDAC) Inhibitors Market

• 14.1. South Korea Histone Deacetylase (HDAC) Inhibitors Market Overview
• 14.2. South Korea Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Histone Deacetylase (HDAC) Inhibitors Market

• 15.1. Western Europe Histone Deacetylase (HDAC) Inhibitors Market Overview
• 15.2. Western Europe Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Histone Deacetylase (HDAC) Inhibitors Market

• 16.1. UK Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Histone Deacetylase (HDAC) Inhibitors Market

• 17.1. Germany Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Histone Deacetylase (HDAC) Inhibitors Market

• 18.1. France Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Histone Deacetylase (HDAC) Inhibitors Market

• 19.1. Italy Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Histone Deacetylase (HDAC) Inhibitors Market

• 20.1. Spain Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Histone Deacetylase (HDAC) Inhibitors Market

• 21.1. Eastern Europe Histone Deacetylase (HDAC) Inhibitors Market Overview
• 21.2. Eastern Europe Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Histone Deacetylase (HDAC) Inhibitors Market

• 22.1. Russia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Histone Deacetylase (HDAC) Inhibitors Market

• 23.1. North America Histone Deacetylase (HDAC) Inhibitors Market Overview
• 23.2. North America Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Histone Deacetylase (HDAC) Inhibitors Market

• 24.1. USA Histone Deacetylase (HDAC) Inhibitors Market Overview
• 24.2. USA Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Histone Deacetylase (HDAC) Inhibitors Market

• 25.1. Canada Histone Deacetylase (HDAC) Inhibitors Market Overview
• 25.2. Canada Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Histone Deacetylase (HDAC) Inhibitors Market

• 26.1. South America Histone Deacetylase (HDAC) Inhibitors Market Overview
• 26.2. South America Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Histone Deacetylase (HDAC) Inhibitors Market

• 27.1. Brazil Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Histone Deacetylase (HDAC) Inhibitors Market

• 28.1. Middle East Histone Deacetylase (HDAC) Inhibitors Market Overview
• 28.2. Middle East Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Histone Deacetylase (HDAC) Inhibitors Market

• 29.1. Africa Histone Deacetylase (HDAC) Inhibitors Market Overview
• 29.2. Africa Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Histone Deacetylase (HDAC) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Histone Deacetylase (HDAC) Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. Histone Deacetylase (HDAC) Inhibitors Market Competitive Landscape
• 30.2. Histone Deacetylase (HDAC) Inhibitors Market Company Profiles
  • 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abcam plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Pharmacyclics LLC Overview, Products and Services, Strategy and Financial Analysis

31. Histone Deacetylase (HDAC) Inhibitors Market Other Major And Innovative Companies

• 31.1. R&D Systems Inc.
• 31.2. Tenaya Therapeutics Inc.
• 31.3. Syndax Pharmaceuticals Inc.
• 31.4. Italfarmaco SpA
• 31.5. InvivoGen Corporation
• 31.6. TCI Chemicals (India) Pvt. Ltd.
• 31.7. 4SC AG
• 31.8. Medivir AB
• 31.9. Mirati Therapeutics Inc.
• 31.10. Spectrum Pharmaceuticals Inc.
• 31.11. Curis Inc.
• 31.12. Acetylon Pharmaceuticals Inc.
• 31.13. Oryzon Genomics SA
• 31.14. Xynomic Pharmaceuticals Inc.
• 31.15. Celleron Therapeutics Ltd.

32. Global Histone Deacetylase (HDAC) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Histone Deacetylase (HDAC) Inhibitors Market

34. Recent Developments In The Histone Deacetylase (HDAC) Inhibitors Market

35. Histone Deacetylase (HDAC) Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 Histone Deacetylase (HDAC) Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Histone Deacetylase (HDAC) Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Histone Deacetylase (HDAC) Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer